首页|The isoxazole based flavonoid derivative 1 ameliorates non-alcoholic fatty liver disease in high-fat diet-induced obese mice by regulating lipid metabolism and inflammatory responses
The isoxazole based flavonoid derivative 1 ameliorates non-alcoholic fatty liver disease in high-fat diet-induced obese mice by regulating lipid metabolism and inflammatory responses
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
? 2022 Phytochemical Society of EuropeGlobally, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease, and has attracted considerable research traction in the literature. However, no effective drugs have yet been approved by the Food and Drug Administration. In this study, a new isoxazole derivative (1), which activated AMPK and reduced gluconeogenesis levels, was evaluated in HFD-induced obese mice for NAFLD treatment. Our results showed that 1 reduced body weight gain and attenuated metabolic disorder in these mice. Underlying mechanisms revealed that 1 alleviated hepatic steatosis by activating AMPK, and inflammatory responses by inhibiting NF-κB. Our study suggested that 1 may be clinically valuable as an NAFLD therapeutic candidate.
Ni T.-W.、Han T.-T.、Li Y.-R.、Zhang C.、Qin N.、Wang Y.-S.、Duan H.-Q.、Chen Y.、Duan X.-C.
展开 >
Tianjin Key Laboratory of Retinal Functions and Diseases Tianjin Branch of National Clinical Research Center for Ocular Disease Eye Institute and School of Optometry Tianjin Medical University Eye Hospital
NSTL
Elsevier
